

# PharmaEssentia Corporation

TWSE: 6446

---

P R E S S   R E L E A S E

For Immediate Release

## PharmaEssentia Partners with Japan's TECH-Tokyo to Launch the Inaugural PharmaEssentia Innovation Award

*Launching in March — Supporting Biomedical Startups on the Path to Global Markets*

**TAIPEI, TAIWAN — [March 29, 2026]** — PharmaEssentia Corporation (TWSE: 6446) today announced the launch of the **PharmaEssentia Innovation Award**, a new initiative designed to identify and support biotech and healthcare startup teams with strong global commercialization potential. The inaugural PharmaEssentia Innovation Award will be held in partnership with TECH-Tokyo, a leading innovation platform in Japan, and will simultaneously invite biomedical startup teams from Taiwan and Japan to participate — fostering Taiwan–Japan collaboration in biotech and healthcare innovation and accelerating breakthrough biomedical technologies and products toward global markets.

Applications for the inaugural PharmaEssentia Innovation Award open today. The Grand Prize carries an award of USD \$100,000, with a total prize pool of USD \$200,000. The company noted that the award is designed to go well beyond research funding: the introduction of industry resources, and knowledge sharing, the PharmaEssentia Innovation Award aims to promote frontier technology exchange and accelerate startup innovations toward clinical development and global commercialization.

As the global pharmaceutical industry evolves rapidly, biotech innovation increasingly extends beyond the internal R&D efforts of any single company, with growing opportunities emerging from cross-disciplinary and cross-border collaboration networks. Guided by the philosophy of “build connections, enable collaboration, and drive innovation,” the PharmaEssentia Innovation Award seeks to create a cross-border platform that connects academic research capabilities, startup momentum, and international industry resources — fostering exchange, elevating value, and laying the groundwork for potential future strategic collaborations.

The PharmaEssentia Innovation Award focuses on strategic areas closely aligned with the company's core R&D direction and global footprint, and invites startup teams with breakthrough therapeutic innovation potential to apply. Eligible submissions span innovative drug R&D in hematology, oncology, rare diseases, and autoimmune disorders; technology platforms leveraging artificial intelligence (AI) and machine learning (ML) to accelerate drug discovery and development; and ex vivo or in vivo cell therapy technology platforms. The review panel will include distinguished experts from Harvard University in the United States, along with leaders from industry, government, academia, and research institutions in Taiwan and Japan. Their expertise spans hematology, oncology, and immunology, combining outstanding academic achievement with deep industry experience to ensure that evaluations balance scientific innovation, clinical application value, and global market development potential.

PharmaEssentia stated that it looks forward to partnering with TECH-Tokyo on the inaugural PharmaEssentia Innovation Award to jointly advance Taiwan–Japan collaboration across innovative R&D, academic exchange, and industry application, and to develop concrete, long-term strategic partnership opportunities. In future editions, the program plans to expand its reach by inviting startup teams from additional countries — continuing to bring innovative treatment options to patients worldwide while strengthening the international visibility and impact of Taiwan's biotech industry.

**For more information on how to apply for the PharmaEssentia Innovation Award, please visit:**

**<https://tech-tokyo.org/pharmaessentiainnovationaward2026/>**

**PharmaEssentia Innovation Award Contact**

**Annie Lin**

Email: [annie\\_lin@pharmaessentia.com](mailto:annie_lin@pharmaessentia.com)

---

## **About TECH-Tokyo**

The Technology Exchange and Collaboration Hub in Tokyo (TECH-Tokyo G.K.) is dedicated to bridging the gap between world-renowned university faculty and researchers, entrepreneurs, and Japanese companies, entrepreneurs, investors, and academic institutions. Through its long-running program series — encompassing presentations, lectures, workshops, networking events, distinguished guest speakers, and competitions — TECH-Tokyo fosters robust collaborations through licensing, partnerships, investments into university spinoffs, and sponsored research, while also facilitating academic exchange and executive education. For more information, visit <https://tech-tokyo.org/>

## **About PharmaEssentia Corporation**

PharmaEssentia Corporation (TWSE: 6446) was founded in October 2003 by a team of distinguished scientists with deep expertise in new drug development. Building on its proprietary PEGylation technology platform for the development of novel, long-acting biologic therapies, as well as advanced small-molecule synthesis capabilities, and leveraging a model of multinational R&D collaboration, the company develops a portfolio of next-generation breakthrough therapies to help patients combat hematologic malignancies, chronic hepatitis, and serious cancers. PharmaEssentia is a fully integrated pharmaceutical company headquartered in Taiwan, engaged in innovative drug discovery, clinical development, manufacturing, and global commercialization. For more information, please visit <http://www.pharmaessentia.com>

---

## **Forward-Looking Statements**

This document and related information released concurrently contain forward-looking statements. Except for statements of historical fact, all statements regarding PharmaEssentia's (the "Company's") future operations, possible events, and outlook — including but not limited to forecasts, targets, estimates, and operating plans — are forward-looking statements. Forward-looking statements are subject to various factors and uncertainties that may cause actual results to differ materially from those expressed or implied, including but not limited to price fluctuations, actual demand, exchange-rate changes, market share, competitive conditions, changes in legal, financial, and regulatory frameworks, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the Company's control. These forward-looking statements are based on current forecasts and evaluations, and the Company undertakes no obligation to update them in the future.

---

## **PharmaEssentia Media Contact**

### **Yoko Naito**

Tel: 080-8822-3135

Email: [yoko\\_naito@pharmaessentia.com](mailto:yoko_naito@pharmaessentia.com)

###